Deng, Jiehui
Thennavan, Aatish
Dolgalev, Igor http://orcid.org/0000-0003-4451-126X
Chen, Ting http://orcid.org/0000-0003-1725-7956
Li, Jie http://orcid.org/0000-0003-2400-9790
Marzio, Antonio
Poirier, John T. http://orcid.org/0000-0001-9795-5644
Peng, David H.
Bulatovic, Mirna
Mukhopadhyay, Subhadip
Silver, Heather
Papadopoulos, Eleni
Pyon, Val
Thakurdin, Cassandra
Han, Han
Li, Fei
Li, Shuai
Ding, Hailin
Hu, Hai
Pan, Yuanwang
Weerasekara, Vajira
Jiang, Baishan http://orcid.org/0000-0001-6796-9500
Wang, Eric S.
Ahearn, Ian
Philips, Mark http://orcid.org/0000-0002-1179-8156
Papagiannakopoulos, Thales
Tsirigos, Aristotelis http://orcid.org/0000-0002-7512-8477
Rothenberg, Eli http://orcid.org/0000-0002-1382-1380
Gainor, Justin http://orcid.org/0000-0001-8697-4081
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Hammerman, Peter S.
Pagano, Michele http://orcid.org/0000-0003-3210-2442
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Bardeesy, Nabeel http://orcid.org/0000-0003-3867-0416
Wong, Kwok-Kin http://orcid.org/0000-0001-6323-235X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 CA009161, R01CA76584, SPORE CA058223, R01CA219670, R01CA219670)
Article History
Received: 17 November 2020
Accepted: 9 April 2021
First Online: 17 May 2021
Competing interests
: The authors declare the following competing interests: K.-K.W. is a founder and equity holder of G1 Therapeutics. K.-K.W. has sponsored Research Agreements with MedImmune, Takeda, TargImmune, Mirati, Merus, Alkermes and BMS. K.-K.W. has consulting and sponsored research agreements with AstraZeneca, Janssen, Pfizer, Novartis, Merck, Ono, Array. C.M.P is an equity stock holder and consultant, and Board of Director Member of BioClassifier LLC and GeneCentric Diagnostics. C.M.P is also listed an inventor on patent applications on the Breast PAM50 and Lung Cancer Subtyping assays. C.M.R. has consulted regarding cancer drug development with AbbVie, Amgen, Ascentage, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Loxo and PharmaMar, and serves on the SAB of Bridge Medicines and Harpoon Therapeutics. M.Pagano is a cofounder of Coho Therapeutics; has financial interests in Coho Therapeutics, CullGen Inc. and Kymera Therapeutics; is on the SAB of CullGen Inc. and Kymera Therapeutics, and is a consultant for Coho Therapeutics, CullGen Inc., Kymera Therapeutics and SEED Therapeutics. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, EMD Serono, Gilead, AstraZeneca, Pfizer, Incyte, Novartis, Merck, Agios, Amgen and Array; research support from Novartis, Genentech/Roche and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis and Alexo; and has an immediate family member who is an employee of Ironwood Pharmaceuticals. G.J.F. has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic and Novartis. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant and GV20. G.J.F. has equity in NextPoint, Triursus, Xios, iTeos, IgM and GV20.